Insider Selling: uniQure (NASDAQ:QURE) Director Sells 21,167 Shares

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the transaction, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 17th, Jack Kaye sold 5,295 shares of uniQure stock. The shares were sold at an average price of $42.57, for a total value of $225,408.15.
• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45.

uniQure Stock Down 7.4%

QURE traded down $3.36 on Thursday, reaching $41.81. 2,806,126 shares of the company traded hands, compared to its average volume of 2,743,461. The stock’s 50 day moving average price is $29.56 and its 200-day moving average price is $23.58. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a market cap of $2.64 billion, a price-to-earnings ratio of -12.01 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. On average, sell-side analysts expect that uniQure N.V. will post -3.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Aberdeen Group plc lifted its holdings in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp boosted its position in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Finally, Orbimed Advisors LLC raised its stake in shares of uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across several years and maintained a Buy rating with an $80 price target, reinforcing bullish long-term expectations for uniQure. Article Title
• Positive Sentiment: Zacks said uniQure is trading above a golden cross, a technical pattern that can attract momentum buyers. Article Title
• Neutral Sentiment: A market article compared uniQure with Viridian Therapeutics, which may have prompted some relative-value interest but does not appear to reflect a company-specific catalyst. Article Title
• Negative Sentiment: Insider Walid Abi-Saab sold shares again, which can pressure sentiment even though the sale was modest in size. Article Title

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Leerink Partners lifted their price target on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. HC Wainwright increased their price target on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a report on Monday. Mizuho raised their price target on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Finally, The Goldman Sachs Group upped their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.